Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
CONCLUSION: In this study, desidustat was found to be noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and it was well-tolerated. Clinical Trial Registry Identifier: CTRI/2019/12/022312 (India).PMID:35462369 | DOI:10.1159/000523949 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - April 24, 2022 Category: Urology & Nephrology Authors: Sishir Gang Prakash Khetan Deepak Varade Venkata Ramakrishna Chinta Siddharth Mavani Umesh Gupta S Venkata Krishna Reddy Sunil Rajanna Tarun Jeloka Vivek Ruhela Kevinkumar Kansagra Pooja Kanani Jayesh Bhatt Kuldipsinh Zala Study Investigator Group Source Type: research
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
Conclusion: In this study, desidustat was found to be noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and it was well-tolerated.Clinical Trial Registry Identifier: CTRI/2019/12/022312 (India).Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - April 22, 2022 Category: Neurology Source Type: research
Cohort profile: Alliance for Quality Assessment in Healthcare-Dialysis (AQuAH-D) prospective cohort study of patients on haemodialysis in Japan
Purpose
The global burden of kidney failure is increasing, but the treatment of kidney failure varies widely between patients, between dialysis facilities and over time. The Alliance for Quality Assessment in Healthcare-Dialysis (AQuAH-D) aims to conduct efficient and timely cohort studies on associations between those variations and clinical and patient-reported outcomes.
Participants
Included are outpatients aged 20 years old or older who are undergoing haemodialysis and have consented to participate. A total of 2895 patients were enrolled from 25 facilities in Japan between August 2018 and July 2020 and are to be follo...
Source: BMJ Open - January 25, 2022 Category: General Medicine Authors: Shimizu, S., Onishi, Y., Kabaya, K., Wang, J., Fukuma, S., Morinaga, J., Hatakeyama, S., Kobayashi, S., Maeno, K., Yamazaki, H., Fukuhara, S. Tags: Open access, Epidemiology Source Type: research
Retacrit ®, Biosimilar of Epoetin alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation
Introduction. To evaluate in real-life conditions the effectiveness and safety of a biosimilar of epoetin alpha (Retacrit ®) in chemotherapy-induced anemia and the impact of iron supplementation.
Methods. This was a longitudinal, observational, prospective study of 12–16 weeks conducted in 195 French centers. The primary endpoint was the achievement of target Hb (with an increase of Hb 1 g/dL) or an increase of H b 2 g/dL, in the absence of transfusion in the previous 3 weeks.
Results. 2076 patients (women, 50.6%; mean age, 67.0 years) with malignant diseases (solid tumors, 79.8%; lymphomas, 12.7%; multiple myelom...
Source: Oncology - January 20, 2022 Category: Cancer & Oncology Source Type: research
Retacrit ®, Biosimilar of Epoetin alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation
CONCLUSION: Epoetin alpha biosimilar was effective and well tolerated for treating chemotherapy-induced anemia. Patients in subgroup with iron supplementation had lower TSAT at inclusion compared to subgroup without supplementation. Comparable mean Hb levels were achieved in both subgroups. The rate of patients with iron supplementation through the intravenous route was however insufficient.PMID:35051930 | DOI:10.1159/000522069 (Source: Oncology)
Source: Oncology - January 20, 2022 Category: Cancer & Oncology Authors: Kamel Laribi Dominique Spaeth Florian Scotte Isabelle Ray-Coquard Source Type: research
Retacrit ®, Biosimilar of Epoetin alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation
CONCLUSION: Epoetin alpha biosimilar was effective and well tolerated for treating chemotherapy-induced anemia. Patients in subgroup with iron supplementation had lower TSAT at inclusion compared to subgroup without supplementation. Comparable mean Hb levels were achieved in both subgroups. The rate of patients with iron supplementation through the intravenous route was however insufficient.PMID:35051930 | DOI:10.1159/000522069 (Source: Oncology)
Source: Oncology - January 20, 2022 Category: Cancer & Oncology Authors: Kamel Laribi Dominique Spaeth Florian Scotte Isabelle Ray-Coquard Source Type: research
Retacrit ®, Biosimilar of Epoetin alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation
CONCLUSION: Epoetin alpha biosimilar was effective and well tolerated for treating chemotherapy-induced anemia. Patients in subgroup with iron supplementation had lower TSAT at inclusion compared to subgroup without supplementation. Comparable mean Hb levels were achieved in both subgroups. The rate of patients with iron supplementation through the intravenous route was however insufficient.PMID:35051930 | DOI:10.1159/000522069 (Source: Oncology)
Source: Oncology - January 20, 2022 Category: Cancer & Oncology Authors: Kamel Laribi Dominique Spaeth Florian Scotte Isabelle Ray-Coquard Source Type: research
Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone
Intern Med. 2021 Dec 28. doi: 10.2169/internalmedicine.8823-21. Online ahead of print.ABSTRACTPure red cell aplasia (PRCA) associated with erythropoiesis-stimulating agents (ESAs), which were first reported in 1998, usually occurs with subcutaneous administration of epoetin alfa (Eprex®). Improvements in ESA storage, handling, and administration methods have reduced the PRCA incidence. Continuous erythropoietin receptor activator (CERA) is a third-generation ESA that is rarely reported to induce PRCA. We herein report a case of CERA-induced PRCA presenting with positive anti-erythropoietin (EPO) and anti-CERA antibodies, ...
Source: Internal Medicine - January 4, 2022 Category: Internal Medicine Authors: Nozomi Okahashi Masayuki Kubo Ei Hoshino Masahito Uchihara Itsuto Amano Haruyuki Tanaka Source Type: research
Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex ® in patients with anaemia of chronic renal failure
(Source: BMC Nephrology)
Source: BMC Nephrology - January 3, 2022 Category: Urology & Nephrology Authors: Soo Kun Lim, Bak Leong Goh, Ravindran Visvanathan, Su Hyun Kim, Jin Seok Jeon, Sung Gyun Kim, Jae Hyun Chang, Chun Soo Lim and Zaki Morad Tags: Correction Source Type: research
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
CONCLUSION: Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA. Furthermore, CRP is recommended to be routinely measured where patients with higher CRP require high ESA doses.PMID:34814819 | DOI:10.2174/1568009621666211123095129 (Source: Current Drug Safety)
Source: Current Drug Safety - November 24, 2021 Category: Drugs & Pharmacology Authors: Nahla E El-Ashmawy Eman G Khedr Nahla S Kotb Fathi Salem Amera O Ibrahim Source Type: research
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
CONCLUSION: Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA. Furthermore, CRP is recommended to be routinely measured where patients with higher CRP require high ESA doses.PMID:34814819 | DOI:10.2174/1568009621666211123095129 (Source: Current Drug Safety)
Source: Current Drug Safety - November 24, 2021 Category: Drugs & Pharmacology Authors: Nahla E El-Ashmawy Eman G Khedr Nahla S Kotb Fathi Salem Amera O Ibrahim Source Type: research
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
CONCLUSION: Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA. Furthermore, CRP is recommended to be routinely measured where patients with higher CRP require high ESA doses.PMID:34814819 | DOI:10.2174/1568009621666211123095129 (Source: Current Drug Safety)
Source: Current Drug Safety - November 24, 2021 Category: Drugs & Pharmacology Authors: Nahla E El-Ashmawy Eman G Khedr Nahla S Kotb Fathi Salem Amera O Ibrahim Source Type: research
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
CONCLUSION: Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA. Furthermore, CRP is recommended to be routinely measured where patients with higher CRP require high ESA doses.PMID:34814819 | DOI:10.2174/1568009621666211123095129 (Source: Current Drug Safety)
Source: Current Drug Safety - November 24, 2021 Category: Drugs & Pharmacology Authors: Nahla E El-Ashmawy Eman G Khedr Nahla S Kotb Fathi Salem Amera O Ibrahim Source Type: research
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
CONCLUSION: Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA. Furthermore, CRP is recommended to be routinely measured where patients with higher CRP require high ESA doses.PMID:34814819 | DOI:10.2174/1568009621666211123095129 (Source: Current Drug Safety)
Source: Current Drug Safety - November 24, 2021 Category: Drugs & Pharmacology Authors: Nahla E El-Ashmawy Eman G Khedr Nahla S Kotb Fathi Salem Amera O Ibrahim Source Type: research
Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
CONCLUSION: Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA. Furthermore, CRP is recommended to be routinely measured where patients with higher CRP require high ESA doses.PMID:34814819 | DOI:10.2174/1568009621666211123095129 (Source: Current Drug Safety)
Source: Current Drug Safety - November 24, 2021 Category: Drugs & Pharmacology Authors: Nahla E El-Ashmawy Eman G Khedr Nahla S Kotb Fathi Salem Amera O Ibrahim Source Type: research
